1. Aaronson, NK, Acquadro, C, Alonso, J et al. , International quality of life assessment (IQOLA) project. Qual Life Res. 1992;1:349–351.
2. Agency for Healthcare Research & Quality. US Department of Health & Human Services. National Guideline Clearinghouse. www.guideline.gov (accessed December 18, 2008).
5. Bellamy, N. WOMAC osteoarthritis index- user guide VII. Brisbane, Australia: 2004.
6. Bellamy, N, Buchanan, WW, Goldsmith, CH, Campbell, J, Stitt, LW. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–1840.
7. Berry, DJ, Harmsen, WS, Cabanela, ME, Morrey, BF. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am. 2002;84:171–177.
8. Boutron, I, Moher, D, Altman, DG, Schulz, KF, Ravaud, P, CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: Explanation and elaboration. Ann Intern Med. 2008;148:295–309.
9. Brunenberg, DE van Steyn, MJ, Sluimer, JC et al. , Joint recovery programme versus usual care: An economic evaluation of a clinical pathway for joint replacement surgery. Med Care. 2005;43:1018–1026.
11. Clark, DO, Von Korff, M, Saunders, K, Baluch, WM, Simon, GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783–795.
12. Cushnaghan, J, Bennett, J, Reading, I et al. , Long-term outcome following total knee arthroplasty: A controlled longitudinal study. Ann Rheum Dis. 2008 [Epub ahead of print].
13. Darer, J, Pronovost, P, Bass, EB. Use and evaluation of critical pathways in hospitals. Eff Clin Pract. 2002;5:114–119.
14. Dixon, T, Shaw, ME, Dieppe, PA. Analysis of regional variation in hip and knee joint replacement rates in England using hospital episodes statistics. Public Health. 2006;120:83–90.
15. Dowsey, MM, Kilgour, ML, Santamaria, NM, Choong, PF. Clinical pathways in hip and knee arthroplasty: A prospective randomised controlled study. Med J Aust. 1999;170:59–62.
16. Dy, SM, Garg, P, Nyberg, D et al. , Critical pathway effectiveness: Assessing the impact of patient, hospital care, and pathway characteristics using qualitative comparative analysis. Health Serv Res. 2005;40:499–516.
17. El Baz, N, Middel, B, van Dijk, JP et al. , Are the outcomes of clinical pathways evidence-based? A critical appraisal of clinical pathway evaluation research. J Eval Clin Pract. 2007;13:920–929.
18. Ernst, E, Canter, PH. Limitations of “pragmatic” trials. Postgrad Med J. 2005;81:203.
19. Freemantle, N, Blonde, L, Bolinder, B et al. , Real-world trials to answer real-world questions. Pharmacoeconomics. 2005;23:747–754.
20. Garrison, LP Jr, Neumann, PJ, Erickson, P, Marshall, D, Mullins, CD. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health. 2007;10:326–35.
21. Glasgow, RE, Magid, DJ, Beck, A, Ritzwoller, D, Estabrooks, PA. Practical clinical trials for translating research to practice: Design and measurement recommendations. Med Care. 2005;43:551–557.
23. Healy, WL, Ayers, ME, Iorio, R et al. , Impact of a clinical pathway and implant standardization on total hip arthroplasty: A clinical and economic study of short-term patient outcome. J Arthroplasty. 1998;13:266–276.
24. Jain, NB, Higgins, LD, Ozumba, D et al. , Trends in epidemiology of knee arthroplasty in the United States, 1990–2000. Arthritis Rheum. 2005;52:3928–3933.
25. Joint Replacement Unit, Sahlgrenska University Hospital. Swedish Hip Arthroplasty Register annual report 2006. www.jru.orthop.gu.se (accessed November 21, 2008).
26. Lin, YK, Su, JY, Lin, GT et al. , Impact of a clinical pathway for total knee arthroplasty. Kaohsiung J Med Sci. 2002;18:134–140.
27. Lingard, EA, Berven, S, Katz, JN, Kinemax Outcomes Group. Management and care of patients undergoing total knee arthroplasty: Variations across different health care settings. Arthritis Care Res. 2000;13:129–136.
28. Macario, A, Horne, M, Goodman, S et al. , The effect of a perioperative clinical pathway for knee replacement surgery on hospital costs. Anesth Analg. 1998;86:978–984.
29. Macdonald, SJ, Charron, KD, Bourne, RB et al. , The John Insall Award: Gender-specific total knee replacement: Prospectively collected clinical outcomes. Clin Orthop Relat Res. 2008;466:2612–2616.
30. Macpherson, H. Pragmatic clinical trials. Complement Ther Med. 2004;12:136–140.
31. McMahon, AD. Study control, violators, inclusion criteria and defining explanatory and pragmatic trials. Stat Med. 2002;21:1365–1376.
33. Panella, M, Marchisio, S, Di Stanislao, F. Reducing clinical variations with clinical pathways: Do pathways work? Int J Qual Health Care. 2003;15:509–521.
34. Pearson, SD, Kleefield, SF, Soukop, JR, Cook, EF, Lee, TH. Critical pathways intervention to reduce length of hospital stay. Am J Med. 2001;110:175–180.
35. Pennington, JM, Jones, DP, McIntyre, S. Clinical pathways in total knee arthroplasty: A New Zealand experience. J Orthop Surg (Hong Kong). 2003;11:166–173.
36. Renholm, M, Leino-Kilpi, H, Suominen, T. Critical pathways. A systematic review. J Nurs Adm. 2002;32:196–202.
37. Rissanen, P, Aro, S, Sintonen, H, Slatis, P, Paavolainen, P. Quality of life and functional ability in hip and knee replacements: A prospective study. Qual Life Res. 1996;5:56–64.
38. Roland, M, Torgerson, DJ. What are pragmatic trials? BMJ. 1998;316:285.
39. Roos EM. Effectiveness and practice variation of rehabilitation after joint replacement. Curr Opin Rheumatol. 2003;15:160–162.
40. Schwartz, D, Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637–648.
41. Teutsch, SM, Berger, ML, Weinstein, MC. Comparative effectiveness: Asking the right questions, choosing the right method. Health Aff (Millwood). 2005;24:128–132.
42. Tunis, SR, Stryer, DB, Clancy, CM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–1632.
43. Vanhaecht, K, Sermeus, W, Tuerlinckx, G et al. , Development of a clinical pathway for total knee arthroplasty and the effect on length of stay and in-hospital functional outcome. Acta Orthop Belg. 2005;71:439–444.
44. Walter, FL, Bass, N, Bock, G, Markel, DC. Success of clinical pathways for total joint arthroplasty in a community hospital. Clin Orthop Relat Res. 2007;457:133–137.
45. Wertheimer, AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21:233–234, 239–241, 258.
46. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD applications. http://www.whocc.no/atcddd/ (accessed January 16, 2009).
47. Wilensky, GR. Developing a center for comparative effectiveness information. Health Aff (Millwood). 2006;25:w572–w585.
48. Zwarenstein, M, Treweek, S, Gagnier, JJ et al. , Improving the reporting of pragmatic trials: An extension of the CONSORT statement. BMJ. 2008;337:a2390.